Represents the clinical development milestone payment received by the entity during the period.

No definition available.

Name:	depo_ClinicalDevelopmentMilestonePaymentReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the milestone payment received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_MilestonePaymentReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the milestone payments following FDA's Acceptance.

+ References

No definition available.

+ Details

Name:	depo_MilestonePaymentsFollowingFDAsAcceptance
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of milestone payments received.

+ References

No definition available.

+ Details

Name:	depo_NumberOfMilestonePaymentsReceived
Namespace Prefix:	depo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of products elected to developed by utilizing Acuform technology under the agreement.

+ References

No definition available.

+ Details

Name:	depo_NumberOfProductsElectedToDevelop
Namespace Prefix:	depo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of products to be developed by utilizing Acuform technology under the agreement.

+ References

No definition available.

+ Details

Name:	depo_NumberOfProductsToBeDeveloped
Namespace Prefix:	depo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of projects completed under the agreement.

+ References

No definition available.

+ Details

Name:	depo_NumberOfProjectsCompleted
Namespace Prefix:	depo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalties required to be paid to the entity, as a percentage of net product sales, in year five and thereafter of agreement.

+ References

No definition available.

+ Details

Name:	depo_RoyaltyPercentageYearFiveAndThereafter
Namespace Prefix:	depo_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalties required to be paid to the entity, as a percentage of net product sales, in year one of agreement.

+ References

No definition available.

+ Details

Name:	depo_RoyaltyPercentageYearOne
Namespace Prefix:	depo_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalties required to be paid to the entity, as a percentage of net product sales, in years three and four of agreement.

+ References

No definition available.

+ Details

Name:	depo_RoyaltyPercentageYearsThreeAndFour
Namespace Prefix:	depo_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalties required to be paid to the entity, as a percentage of net product sales, in year two of agreement.

+ References

No definition available.

+ Details

Name:	depo_RoyaltyPercentageYearTwo
Namespace Prefix:	depo_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the upfront agreement fee received by the entity for formulation work to be performed under the agreement during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeeForFormulationWorkReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront agreement fee received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeeReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront agreement fees and milestone payments received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeesAndMilestonesPaymentReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront agreement fees, initial product formulation work and milestone payments received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeesInitialProductFormulationWorkAndMilestonePaymentsReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25383-109308

+ Details

Name:	us-gaap_RecordedUnconditionalPurchaseObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_IronwoodPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_JanssenPharmaceuticaNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_MallinckrodtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_PatheonPuertoRicoIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_SalixPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_ValeantPharmaceuticalsInternationalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSE AND COLLABORATIVE ARRANGEMENTS (Details) (USD $)	12 Months Ended			1 Months Ended			3 Months Ended		74 Months Ended	1 Months Ended		3 Months Ended		11 Months Ended	1 Months Ended		42 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2014	Apr. 30, 2014	Nov. 30, 2008 item	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014 item	Aug. 31, 2012	Aug. 31, 2010	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013 item	Mar. 31, 2014	Jul. 31, 2011	Dec. 31, 2014 item	Aug. 31, 2011	Oct. 01, 2014	Jul. 31, 2008	Jul. 31, 2005	Dec. 31, 2004
License and collaborative arrangements
Revenue recognized	$ 31,515,000us-gaap_LicenseAndServicesRevenue	$ 12,796,000us-gaap_LicenseAndServicesRevenue	$ 18,798,000us-gaap_LicenseAndServicesRevenue
Royalty revenue	1,821,000us-gaap_RoyaltyRevenue	45,003,000us-gaap_RoyaltyRevenue	44,535,000us-gaap_RoyaltyRevenue
Upfront agreement fee deferred revenue balance		15,516,000us-gaap_DeferredRevenue										15,516,000us-gaap_DeferredRevenue		15,516,000us-gaap_DeferredRevenue
Mallinckrodt
License and collaborative arrangements
Number of products to be developed by utilizing Acuform technology						4
Number of products elected to develop						2
Upfront fees and milestones payment received									27,500,000
Upfront fee received									4,000,000
Upfront fee received for formulation work to be performed under the agreement									1,500,000
Number of milestone payments received									4
Clinical development milestone payments									500,000
Milestone payments following FDA's Acceptance	10,000,000								5,000,000
Milestone payment received				5,000,000	10,000,000
Milestone revenue recognized							5,000,000	10,000,000
Janssen Pharmaceuticals, Inc.
License and collaborative arrangements
Upfront fee received										10,000,000
Janssen Pharmaceutica N.V.
License and collaborative arrangements
Upfront fee received											10,000,000
Milestone payment received											10,000,000
Number of projects completed														2
Revenue recognized												1,400,000	2,200,000
Ironwood Pharmaceuticals, Inc.
License and collaborative arrangements
Upfront fees, initial product formulation work and milestone payments received																	3,400,000
Upfront fee received																900,000
Number of milestone payments received																	3
Milestone revenue recognized															1,000,000
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) \| Commercialization Agreement
License and collaborative arrangements
Revenue recognized	3,000,000	1,400,000	3,300,000
Royalties on net product sales, percentage in 2011																		26.50%
Royalties on net product sales, percentage in 2012																		29.50%
Royalties on net product sales, percentage in 2013 and 2014																		32.00%
Royalties on net product sales, percentage in 2015 and beyond																		34.50%
Royalty revenue		42,100,000	42,800,000
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) \| Promotion Agreement
License and collaborative arrangements
Upfront fee received																				12,000,000
Revenue recognized																			1,900,000
Valeant Pharmaceuticals International, Inc.
License and collaborative arrangements
Upfront fee received																					25,000,000	25,000,000
Revenue recognized	12,500,000	1,600,000	1,600,000
Valeant Pharmaceuticals International, Inc. \| 1000mg Glumetza
License and collaborative arrangements
Revenue recognized																			11,300,000
Patheon Puerto Rico, Inc.
License and collaborative arrangements
Non-cancelable purchase orders and minimum purchase obligations	$ 1,300,000								$ 1,300,000								$ 1,300,000